Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

European Respiratory Journal

Volumn 40, Issue 4, 2012, Pages 874-880

  Simonneau, Gérald ^a   Torbicki, Adam ^a   Hoeper, Marius M ^c   Delcroix, Marion ^d   Karlócai, Kristóf ^e   Galièe, Nazzareno ^f   Degano, Bruno ^a   Bonderman, Diana ^g   Kurzyna, Marcin ^b   Efficace, Michela ^h   Giorgino, Ruben ^h   Lang, Irene M ^g  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Haemodynamics; Prostacyclin; Pulmonary arterial hypertension; Randomised controlled trial

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN RECEPTOR; SELEXIPAG; SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUSHING; HUMAN; HYPOTENSION; JAW PAIN; LIMB PAIN; LUNG VASCULAR RESISTANCE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; AGED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PYRAZINES; RECEPTORS, PROSTAGLANDIN; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 84863528040     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00137511     Document Type: Article

References (23)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
3. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
4. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2: 123-137.
5. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 56S-61S.
6. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84.
7. Moncada S, Gryglewsli R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
8. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26: 194-201.
9. Worst SJ, Woods M, Warner TD, et al. Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. Mol Pharmacol 2002; 62: 1147-1153.
10. Stitham J, Arehart EJ, Gleim SR, et al. New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues. Br J Pharmacol 2007; 152: 513-522.
11. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302.
12. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
13. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
14. White RJ. Update on the development of oral prostacyclin analogs for the treatment of PAH. Adv Pulmonary Hypertens 2009; 8: 32-36.
15. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010; 104: 9-21.
16. Kuwano K, Hashino A, Asaki T, et al. NS-304, an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007; 322: 1181-1188.
17. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled trial. Lancet 2001; 358: 1119-1123.
18. Galasko GI, Lahiri A, Barnes SC, et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005; 26: 2269-2276.
19. Galiè N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
20. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
21. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
22. Galiè N, Humbert M, Vachiéry JL, et al. Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
23. Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, NS-304, ameliorates rat pulmonary hypertension with unique relaxant responses of its active form MRE-269 on rat pulmonary artery. J Pharmacol Exp Ther 2008; 326: 691-699.